ECM
KROS icon

ExodusPoint Capital Management’s Keros Therapeutics KROS Stock Holding History

ExodusPoint Capital Management’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-13,360
Closed -$272K – 1853
2025
Q4 		$272K Sell
13,360
-9,615
-42% -$169K ﹤0.01% 1330
2025
Q3 		$363K Buy
+22,975
New +$339K 0.01% 1256
2025
Q2 		– Sell
-18,976
Closed -$193K – 1739
2025
Q1 		$193K Buy
+18,976
New +$220K ﹤0.01% 1303
2024
Q3 		– Sell
-19,940
Closed -$911K – 1875
2024
Q2 		$911K Buy
+19,940
New +$1.07M 0.01% 1054
2023
Q1 		– Sell
-11,823
Closed -$568K – 1958
2022
Q4 		$568K Buy
+11,823
New +$552K 0.01% 1125
2021
Q4 		– Sell
-15,952
Closed -$631K – 2397
2021
Q3 		$631K Buy
+15,952
New +$568K 0.01% 1261

Other funds holding KROS

BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $1.6B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
O
OrbiMed New York $4.59B AUM 125.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $70.4B AUM 20.22% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return